{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:09:03Z","timestamp":1788534543081,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.intimp.2025.115185","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T04:55:34Z","timestamp":1751864134000},"page":"115185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Short-term therapeutic effectiveness of tezepelumab in patients with severe asthma: A real-world study"],"prefix":"10.1016","volume":"162","author":[{"given":"Corrado","family":"Pelaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Iaccino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Crimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Biafora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Dragone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vatrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115185_bb0005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2025.115185_bb0010","doi-asserted-by":"crossref","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2025.115185_bb0015","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1164\/rccm.202009-3631CI","article-title":"Severe adult asthmas: integrating clinical features, biology, and therapeutics to improve outcomes","volume":"203","author":"Wenzel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/17476348.2024.2380072","article-title":"Type 2 severe asthma: pathophysiology and treatment with biologics","volume":"18","author":"Pelaia","year":"2024","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0025","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cea.12881","article-title":"The current and future role of biomarkers in type 2 cytokine-mediated asthma management","volume":"47","author":"Pavord","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.intimp.2025.115185_bb0030","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.3390\/ijms22094369","article-title":"Tezepelumab: a potential new biological therapy for severe refractory asthma","volume":"22","author":"Pelaia","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115185_bb0035","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1358\/dot.2022.58.12.3449205","article-title":"Tezepelumab for asthma","volume":"58","author":"Nolasco","year":"2022","journal-title":"Drugs Today."},{"key":"10.1016\/j.intimp.2025.115185_bb0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2147\/JAA.S342391","article-title":"Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types","volume":"17","author":"Panettieri","year":"2024","journal-title":"J. Asthma Allergy."},{"key":"10.1016\/j.intimp.2025.115185_bb0045","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/all.14196","article-title":"TSLP and IL-33 reciprocally promote each other\u2019s lung protein expression and ILC2 receptor expression to enhance innate type-2 airway inflammation","volume":"75","author":"Toki","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.intimp.2025.115185_bb0050","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/all.12435","article-title":"Myeloid dendritic cells are primed in allergic asthma for thymic stromal lymphopoietin-mediated induction of Th2 and Th9 responses","volume":"69","author":"Froidure","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.intimp.2025.115185_bb0055","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1084\/jem.20051135","article-title":"TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand","volume":"202","author":"Ito","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0060","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/ni1048","article-title":"Human thymic stromal lymphopoietin promotes dendritic cell-mediated CD4+ T cell homeostatic expansion","volume":"5","author":"Watanabe","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115185_bb0065","doi-asserted-by":"crossref","first-page":"904","DOI":"10.4049\/jimmunol.1201808","article-title":"Thymic stromal lymphopoietin amplifies the differentiation of alternatively activated macrophages","volume":"190","author":"Han","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115185_bb0070","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1165\/rcmb.2009-0168OC","article-title":"Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation","volume":"43","author":"Wong","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.intimp.2025.115185_bb0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1378\/chest.11-1782","article-title":"Mast cell-airway smooth muscle crosstalk: the role of thymic stromal lymphopoietin","volume":"142","author":"Kaur","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.intimp.2025.115185_bb0080","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jaci.2015.03.039","article-title":"Thymic stromal lymphopoietin activation of basophils in patients with allergic asthma is IL-3 dependent","volume":"136","author":"Salter","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115185_bb0085","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.chest.2016.10.042","article-title":"Epithelial-derived cytokines in asthma","volume":"151","author":"Mitchell","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.intimp.2025.115185_bb0090","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/all.15609","article-title":"Sounding the alarmins \u2013 the role of alarmin cytokines in asthma","volume":"78","author":"Gauvreau","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.intimp.2025.115185_bb0095","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01397-2023","article-title":"The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma","volume":"63","author":"Russell","year":"2024","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2025.115185_bb0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2222.2008.03151.x","article-title":"Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions","volume":"39","author":"Tanaka","year":"2009","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.intimp.2025.115185_bb0105","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0110","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/all.15986","article-title":"Tezepelumab in patients with allergic and eosinophilic asthma","volume":"79","author":"Caminati","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.intimp.2025.115185_bb0115","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0120","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomized, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0125","doi-asserted-by":"crossref","first-page":"2101700","DOI":"10.1183\/13993003.01700-2021","article-title":"Is tezepelumab more than just an anti-eosinophil drug?","volume":"59","author":"Adatia","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2025.115185_bb0130","first-page":"1","article-title":"Positioning of tezepelumab in severe asthma","volume":"34","author":"Miralles-Lopez","year":"2024","journal-title":"J. Invest. Allergol. Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115185_bb0135","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jaip.2024.05.052","article-title":"Real-world data on tezepelumab in patients with severe asthma in Germany","volume":"12","author":"Biener","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.intimp.2025.115185_bb0140","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/02770903.2024.2349605","article-title":"Early response to Tezepelumab in type-2 severe asthma patients non-responders to other biological treatments: a real-life study","volume":"61","author":"Jimenez-Gomez","year":"2024","journal-title":"J. Asthma"},{"key":"10.1016\/j.intimp.2025.115185_bb0145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15586\/aei.v52i2.1063","article-title":"Real-life experience after 3 months with tezepelumab before marketing approval","volume":"52","author":"Violan","year":"2024","journal-title":"Allergol. Immunopathol. (Madr.)"},{"key":"10.1016\/j.intimp.2025.115185_bb0150","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/02770903.2024.2409987","article-title":"Short-term tezepelumab effectiveness in patients with severe asthma: a multicenter study","volume":"62","author":"Carpagnano","year":"2025","journal-title":"J. Asthma"},{"key":"10.1016\/j.intimp.2025.115185_bb0155","doi-asserted-by":"crossref","first-page":"76","DOI":"10.15586\/aei.v52i6.1161","article-title":"Four-month real-life response to tezepelumab in patients with multi-failure to other biologics","volume":"52","author":"Betancor","year":"2024","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.intimp.2025.115185_bb0160","first-page":"132","article-title":"Tezepelumab in patients with severe asthma: response at 3 months","volume":"35","author":"Miralles-Lopez","year":"2025","journal-title":"J. Invest. Allergol. Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115185_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.1080153","article-title":"Understanding the development of Th2 cell-driven allergic airway disease in early life","volume":"3","author":"Leon","year":"2023","journal-title":"Front. Allergy."},{"key":"10.1016\/j.intimp.2025.115185_bb0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejim.2024.02.020","article-title":"TSLP is localized in and released from human lung macrophages activated by T2-high and T2-low stimuli: relevance in asthma and COPD","volume":"124","author":"Can\u00e8","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0175","author":"Global Initiative for Asthma"},{"key":"10.1016\/j.intimp.2025.115185_bb0180","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115185_bb0185","doi-asserted-by":"crossref","first-page":"00289","DOI":"10.1183\/23120541.00289-2019","article-title":"Validation of online asthma control questionnaire and asthma quality of life questionnaire","volume":"6","author":"Khusial","year":"2020","journal-title":"ERJ Open. Res."},{"key":"10.1016\/j.intimp.2025.115185_bb0190","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0195","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"European Respiratory Society, ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","author":"American Thoracic Society","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0200","doi-asserted-by":"crossref","first-page":"1600965","DOI":"10.1183\/13993003.00965-2016","article-title":"A European Respiratory Society technical standard: exhaled biomarkers in lung disease","volume":"49","author":"Horvath","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2025.115185_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178900","article-title":"Effects of acute physical exercise on oxidative stress and inflammatory status in young, sedentary obese subjects","volume":"12","author":"Accattato","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2025.115185_bb0210","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/17476348.2023.2226392","article-title":"Defining response to therapy with biologics in severe asthma: from global evaluation to super response and remission","volume":"17","author":"Papaioannou","year":"2023","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0215","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jaci.2012.08.023","article-title":"The asthma control test and the asthma control questionnaire for assessing asthma control: systematic review and meta-analysis","volume":"131","author":"Jia","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115185_bb0220","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/02770903.2023.2297372","article-title":"Patient-reported outcome measures in severe asthma: an expert consensus","volume":"61","author":"Martinez-Moragon","year":"2024","journal-title":"J. Asthma"},{"key":"10.1016\/j.intimp.2025.115185_bb0225","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral-corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0230","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"The severe asthma network in Italy: findings and perspectives","volume":"7","author":"Heffler","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.intimp.2025.115185_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2018.12.001","article-title":"Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data for the severe asthma network in Italy (SANI) registry","volume":"12","author":"Canonica","year":"2019","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.intimp.2025.115185_bb0240","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2023.02.021","article-title":"Anti-epithelial derived cytokines for severe asthma: systematic review and meta-analysis","volume":"151","author":"Su","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115185_bb0245","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaci.2022.11.021","article-title":"Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesan network meta-analysis","volume":"151","author":"Nopsopon","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115185_bb0250","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodeling, and hyperresponsiveness in patients with moderate-to-severe asthma (CASCADE): a double-blind, randomized, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0255","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0260","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/DDDT.S250825","article-title":"Tezepelumab as emerging therapeutic option for the treatment of severe asthma: evidence to date","volume":"15","author":"Dorey-Stein","year":"2021","journal-title":"Drug Des. Develop. Ther."},{"key":"10.1016\/j.intimp.2025.115185_bb0265","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00408-022-00579-2","article-title":"Impact of biologic therapy on the small airways asthma phenotype","volume":"200","author":"Chan","year":"2022","journal-title":"Lung"},{"key":"10.1016\/j.intimp.2025.115185_bb0270","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1148\/radiol.2021204616","article-title":"Mucus plugs in asthma at CT associated with regional ventilation defects at 3He MRI","volume":"303","author":"Mummy","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.intimp.2025.115185_bb0275","article-title":"Tezepelumab and mucus plugs in patients with moderate-to-severe asthma, NEJM","volume":"2","author":"Nordenmark","year":"2023","journal-title":"Evid"},{"key":"10.1016\/j.intimp.2025.115185_bb0280","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature10329","article-title":"TSLP promotes IL-3-independent basophil hematopoiesis and type 2 inflammation","volume":"477","author":"Siracusa","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115185_bb0285","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/iid3.20","article-title":"The effects of thymic stromal lymphopoietin and IL-3 on human eosinophil-basophil lineage commitment: relevance to atopic sensitization","volume":"2","author":"Hui","year":"2014","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.intimp.2025.115185_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156638","article-title":"The role of IL-2 cytokine family in asthma","volume":"180","author":"Goleij","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2025.115185_bb0295","article-title":"Distinct spatial and temporal roles for Th1, Th2, and Th17 cells in asthma","volume":"13","author":"Luo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115185_bb0300","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.anai.2024.09.023","article-title":"Identifying super-responders: a review of the road to asthma remission","volume":"134","author":"Mailhot-Larouche","year":"2025","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.intimp.2025.115185_bb0305","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/JAA.S125948","article-title":"Late-onset asthma: current perspectives","volume":"11","author":"Hirano","year":"2018","journal-title":"J. Asthma Allergy."},{"key":"10.1016\/j.intimp.2025.115185_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2025.05.002","article-title":"Treatable traits as a pathway to remission in asthma","author":"Farinha","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115185_bb0315","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0320","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1164\/rccm.202305-0808OC","article-title":"Association between T2-related comorbidities and effectiveness of biologics in severe asthma","volume":"209","author":"Wechsler","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2025.115185_bb0325","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1164\/rccm.202311-2103ED","article-title":"Do comorbidities influence the response to biologics in severe asthma?","volume":"209","author":"Pelaia","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925011750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925011750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T03:17:38Z","timestamp":1786159058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925011750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":65,"alternative-id":["S1567576925011750"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115185","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term therapeutic effectiveness of tezepelumab in patients with severe asthma: A real-world study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115185"}}